Thoma Bravo-Backed Proofpoint Said to Be in Talks for Varonis
Bloomberg says Thoma Bravo-backed Proofpoint is in talks to acquire Varonis. No deal is signed.
Already have an account? Sign in.
Bloomberg says Thoma Bravo-backed Proofpoint is in talks to acquire Varonis. No deal is signed.
Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.
A patient with highly active relapsing MS died 44 days after receiving BMS’s experimental CD19 CAR-T therapy zola-cel in an early-stage trial.
Bolt Biotherapeutics merges with Prana Therapies in a $120 million deal to advance PRA-216 through Phase 2 trials in asthma, COPD, and atopic dermatitis.
Be the first to know when deals break, stocks move, or biotech headlines hit.